Enovis Corporation (ENOV)

Market Cap	1.40B -43.6%
Revenue (ttm)	2.25B +6.7%
Net Income	-1.18B
EPS	-20.75
Shares Out	57.25M
PE Ratio	n/a
Forward PE	6.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	911,473
Open	24.28
Previous Close	24.32
Day's Range	23.63 - 24.61
52-Week Range	21.00 - 40.70
Beta	1.60
Analysts	Strong Buy
Price Target	48.75 (+98.9%)
Earnings Date	Feb 26, 2026

About ENOV

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary ca...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 8, 2008
• Employees: 7,802
• Stock Exchange: NYSE
• Ticker Symbol: ENOV
• Website: https://www.enovis.com

Financial Performance

In 2025, Enovis's revenue was $2.25 billion, an increase of 6.66% compared to the previous year's $2.11 billion. Losses were -$1.18 billion, 43.5% more than in 2024.

Analyst Summary

According to 8 analysts, the average rating for ENOV stock is "Strong Buy." The 12-month stock price target is $48.75, which is an increase of 98.90% from the latest price.

Price Target

$48.75

(98.90% upside)

Analyst Consensus: Strong Buy